Neurocrine Biosciences, Inc.
NASDAQ:NBIXBiotechnology
-$0.71 today
- Market cap
- $16.48B
- Beta
- 0.40
- P/E (TTM)
- 23.8
- EPS (TTM)
- $6.65
Volume 1.60M
Average 1.18M
NBIX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Neurocrine Biosciences, Inc.NASDAQ: NBIX
Total Equity · Q3 FY2026 · quarter ended Sep 2026
Total equity rises 29.1% from a year ago
Total equity stood at $3.88B at the end of Q3 FY2026, up 29.1% from a year earlier and up 5.0% from the prior quarter. Over 3 fiscal years it compounded at +24.0% a year.
Context
- Total equity amounted to 68.9% of total assets at the end of Q3 FY2026, down 1.5 pp from a year earlier.
- Total equity increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +29.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 3.25B USD
- Year-over-year change
- +25.6%
- 4-year CAGR
- +24.0%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.25B | +25.6% |
| FY2024 | 2024-12-31 | 2.59B | +16.0% |
| FY2023 | 2023-12-31 | 2.23B | +30.7% |
| FY2022 | 2022-12-31 | 1.71B | +24.3% |
| FY2021 | 2021-12-31 | 1.37B | — |
Total Equity vs competitors
How NBIX compares with its peers on the latest reported figures
- NBIX's Sep 2026 total equity of $3.88B is the 2nd highest of the 10 companies compared; the peer median is $280.77M.
- Its year-over-year change of +29.1% is the 3rd highest of 10, against a peer median of -3.1%.
- Total equity amounts to 68.9% of total assets for NBIX, versus a peer median of 64.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $4.19B | +5.9% | +11.9% | 34.9% | |
| Sep 2026 | $3.88B | +29.1% | +24.0% | 68.9% | |
| Sep 2026 | $1.39B | +51.3% | +45.3% | 77.3% | |
| Jun 2026 | $1.03B | -3.1% | +6.2% | 72.2% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $471.51M | +65.0% | +191.8% | 94.8% |
| Mar 2026 | $280.77M | -45.1% | -14.7% | 64.8% | |
| Mar 2026 | $263.38M | -15.1% | +3.8% | 95.7% | |
| Jun 2026 | $83.3M | +14.0% | -6.9% | 10.9% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $70.68M | -69.0% | — | 45.9% |
| Jun 2026 | $12.22M | -90.9% | -54.1% | 3.3% | |
| Peer median (excluding NBIX) | $280.77M | -3.1% | +5.0% | 64.8% | |
Competitors are the stored peer set for NBIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 340.8M | 262.9M | 251.1M | 233M | 713M |
| Short-term Investments | 370.5M | 726.4M | 780.5M | 843.1M | 767.4M |
| Net Receivables | 185.5M | 350M | 439.3M | 479.1M | 686.8M |
| Inventory | 30.5M | 35.1M | 38.3M | 57.4M | 69M |
| Other Current Assets | 45.5M | 79.1M | 97.8M | 63.6M | 115.8M |
| Total Current Assets | 972.8M | 1.45B | 1.61B | 1.72B | 2.52B |
| Property, Plant & Equipment (Net) | 155.8M | 145.6M | 347.3M | 592M | 545.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 37.2M | 35.5M | 36.5M | 0 |
| Long-term Investments | 624.4M | 401.5M | 849.4M | 864.3M | 1.18B |
| Tax Assets | 315.1M | 305.9M | 362.6M | 485.7M | 320.3M |
| Other Non-current Assets | 4.4M | 25M | 49.6M | 15.5M | 59.5M |
| Total Non-current Assets | 1.1B | 915.2M | 1.64B | 1.99B | 2.11B |
| Total Assets | 2.07B | 2.37B | 3.25B | 3.72B | 4.63B |
| Account Payables | 51.5M | 67.3M | 133.3M | 99.9M | 104.9M |
| Short-term Debt | 0 | 169.4M | 170.1M | 0 | 0 |
| Tax Payables | 0 | 9M | 24.4M | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 133.3M | 225.4M | 261.4M | 297.8M | 423.9M |
| Total Current Liabilities | 245.8M | 537.7M | 654.8M | 507.7M | 743.4M |
| Long-term Debt | 335.1M | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 12.3M | 29.7M | 106.3M | 166.2M | 219.7M |
| Total Non-current Liabilities | 452.7M | 123.2M | 364.6M | 621.3M | 635M |
| Total Liabilities | 698.5M | 660.9M | 1.02B | 1.13B | 1.38B |
| Common Stock | 100K | 100K | 100K | 100K | 100K |
| Retained Earnings | (635.8M) | (406.8M) | (157.1M) | 29.2M | 447.7M |
| Accumulated OCI | (1.7M) | (7.9M) | 7M | 5.8M | 13.1M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.37B | 1.71B | 2.23B | 2.59B | 3.25B |
| Total Debt | 440.4M | 262.9M | 428.4M | 455.1M | 415.3M |
| Net Debt | 99.6M | 0 | 177.3M | 222.1M | (297.7M) |
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
Intrinsic Alpha fair value
Locked
Current Price
$162.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.